Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: 20-Hydroxyeicosatetraenoic acid (20-HETE), a metabolite of arachidonic acid catalyzed mainly by cytochrome P450 (CYP) enzymes CYP4A11 and CYP4F2, plays a role in cardiovascular homeostasis. Elevated levels of 20-HETE are associated with hypertension. Accordingly, 20-HETE is a potential target for therapeutic interventions.
Aims: This study aimed to evaluate the effects of commonly prescribed statins simvastatin, atorvastatin, and rosuvastatin on 20-HETE formation in human liver microsomes and to conduct molecular docking simulations with CYP4A11 and CYP4F2.
Methods: Human liver microsomes were used to assess 20-HETE formation inhibition. Molecular docking simulations were performed using predicted structures of CYP4A11, CYP4F2, and CYP4F3B. The binding affinity of simvastatin was evaluated based on lowest energy of binding (LEB) values, and interactions with the heme group were analyzed.
Results: In vitro assay showed that simvastatin, but not other tested statins, inhibited the formation of 20-HETE in the human liver microsome with IC value of 10 µM and in a competitive mechanism as shown in the kinetics of the Lineweaver-Burk plot. Using in silico tools, simvastatin showed a significant inhibitory effect on CYP4A11, CYP4F2, and CYP4F3B with LEB values of -11.06, -9.93, and − 11.55 kcal/mol, respectively, indicating a stronger interaction compared to the known inhibitor HET0016. Simvastatin interacted predominantly with multiple hydrogen bonds and with the heme group of CYP4A11.
Conclusions: Simvastatin effectively inhibits the formation of 20-HETE most probably through interaction with CYP4A11, CYP4F2, and CYP4F3B, suggesting its potential as a therapeutic agent for managing conditions associated with elevated 20-HETE levels. Further clinical investigations are needed to explore its implications in cardiovascular diseases associated with elevated 20-HETE levels.
Clinical Trial Number: Not applicable.
Supplementary Information: The online version contains supplementary material available at 10.1186/s40360-025-00976-2.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12359976 | PMC |
| http://dx.doi.org/10.1186/s40360-025-00976-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Simvastatin inhibits 20-Hydroxyeicosatetraenoic acid formation: docking and in vitro assay.
BMC Pharmacol Toxicol
August 2025
Department of Pharmacology and Pharmacogenomics Research Center, College of Medicine, Inje University, Busan, 50834, Republic of Korea.
Introduction: 20-Hydroxyeicosatetraenoic acid (20-HETE), a metabolite of arachidonic acid catalyzed mainly by cytochrome P450 (CYP) enzymes CYP4A11 and CYP4F2, plays a role in cardiovascular homeostasis. Elevated levels of 20-HETE are associated with hypertension. Accordingly, 20-HETE is a potential target for therapeutic interventions.
View Article and Find Full Text PDFThe CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.
Front Physiol
January 2025
Department of Pharmacology, New York Medical College, Valhalla, NY, United States.
Introduction: Metabolic-dysfunction-associated steatosis liver disease (MASLD) is a progressive liver disease from simple steatosis, steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. Chronic liver diseases (CLDs) can lead to portal hypertension, which is a major cause of complications of cirrhosis. CLDs cause structural alterations across the liver through increased contents of extracellular matrix (ECM), driving dysfunction of liver sinusoidal endothelial cells (LSECs) alongside hepatic stellate cells (HSCs) and activated resident or infiltrating immune cells.
View Article and Find Full Text PDF[Precision Medicine for Patients with Renal Cell Carcinoma Based on Drug-metabolizing Enzyme Expression Levels].
Yakugaku Zasshi
January 2025
Department of Personalized Medicine and Preventive Healthcare Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University.
Notable advances have recently been achieved in drug therapies for renal cell carcinoma (RCC). Several tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) have been approved for metastatic RCC (mRCC). The current first-line treatment for mRCC involves combination therapies using TKIs and ICIs.
View Article and Find Full Text PDFIntroduction of a carboxylic acid group into pyrazolylpyridine derivatives increased selectivity for inhibition of the 20-HETE synthase CYP4A11/4F2.
Bioorg Med Chem
October 2023
Taisho Pharmaceutical Co., Ltd, 1-403, Yoshino-Cho, Kita-Ku, Saitama, Saitama 331-9530, Japan. Electronic address:
20-Hydroxyeicosatetraenoic acid (20-HETE) is a lipid mediator and one of the major arachidonic acid metabolites whose formation is mainly catalyzed by the enzymes cytochrome P450 (CYP) 4F2 and CYP4A11. Several studies have suggested that 20-HETE is involved in the pathogenesis of renal diseases, including diabetic nephropathy and autosomal dominant polycystic kidney disease, and we previously reported compound 1 as a dual inhibitor of CYP4A11/4F2 with therapeutic potential against renal fibrosis. Subsequent studies revealed that compound 1, the dual CYP4A11/4F2 inhibitor, however, exhibited low selectivity over another CYP4F subtype, CYP4F22, which catalyzes ω-hydroxylation of ultra-long-chain fatty acids (ULCFAs); ULCFAs are important for the formation of acylceramides, which play a role in skin barrier formation.
View Article and Find Full Text PDF20-HETE and Hypertension.
Hypertension
October 2024
Department of Pharmacology, University of Mississippi Medical Center, Jackson, MS.
Previous studies established that arachidonic acid is metabolized by the cytochrome P450 (CYP) enzymes of the 4A and 4F families to 20-hydroxyeicosatetraenoic (20-HETE) that regulates renal function and vascular tone. Elevations in the 20-HETE have been reported to increase blood pressure by promoting endothelial dysfunction, vascular inflammation, oxidative stress and endothelial expression of angiotensin-converting enzyme, which increase circulating angiotensin II levels. However, mutations in and that inhibit the formation of 20-HETE have been linked to hypertension in human genetic studies, and a deficiency in 20-HETE promotes sodium retention and hypertension in Dahl salt-sensitive rats.
View Article and Find Full Text PDF